MARKET COMPOSITE
IMRA - Imara Inc
Price
$0.00
+ 0.00 (0.00%)
Imara, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.
Stock Chart
leak data

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra
leak data

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

leak data

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    -- Combined Company to Trade on Nasdaq Under Ticker “ELVN” ---- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA) today announced the results of the special meeting of its stockholders held on February 22, 2023. At the special meeting, Imara’s stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Imara’s common stock to the stockholders of Enliven Therape

    Imara Inc., the blood disorder-focused company that earlier this year cut its staff to just six people, will be no more following a reverse merger with a Colorado biotech.

    Enliven Therapeutics Inc and Imara Inc (NASDAQ: IMRA) agreed to merge in an all-stock transaction. The combined company will focus on advancing Enliven's pipeline of precision oncology product candidates. Enliven is advancing two parallel lead product candidates: ELVN-001 for chronic myeloid leukemia. ELVN-002 for HER2 mutant lung cancer and other HER2-driven tumor types. In September, Imara divested tovinontrine (IMR-687) and all other assets related to its PDE9 program to Cardurion Pharmaceuti

    Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven’s portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additiona

    Here is how Catalyst Pharmaceutical (CPRX) and IMARA Inc. (IMRA) have performed compared to their sector so far this year.

    Here is how IMARA Inc. (IMRA) and Viracta (VIRX) have performed compared to their sector so far this year.

    The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings. Imara Inc. (Nasdaq: IMRA), the blood disorder-focused drugmaker that earlier this year cut its staff to just six employees, has sold its sickle cell disease and beta thalassemia drug to Boston-...

    Yahoo Finance anchors discuss Imara ditching its sickle cell treatment candidate after poor results.

    Imara Inc (NASDAQ: IMRA) has agreed to divest tovinontrine (IMR-687) and all other assets related to its PDE9 program to Cardurion Pharmaceuticals Inc. In addition to $250,000 previously paid by Cardurion upon execution of a non-binding term sheet, the aggregate purchase price consists of an upfront payment of $34.75 million and $60 million as milestone payments. In case of termination, the company would be obligated to pay a fee of $1.5 million Cardurion. In April, Imara posted interim analyses

    Viewing insider transactions for IMARA Inc.'s ( NASDAQ:IMRA ) over the last year, we see that insiders were net buyers...